NUCLEIX

Nucleix Ltd. develops, manufactures and markets highly innovative and non-invasive molecular cancer diagnostic tests.

[NUCLEIX @NUCLEIX2]

This week, two high-quality bladder cancer education events are taking place in Edinburgh: on 28 May 2026 at the Western General Hospital and on 29 May 2026 at the Royal College of Surgeons of Edinburgh. well organised by @ParamMariappan

[NUCLEIX @NUCLEIX2]

Great discussions here at the Portuguese Congress of Urological Oncology, May 8 & 9 in Figueira da Foz. A pleasure to reconnect with Prof José Palma dos Reis during the congress and to exchange perspectives on current developments in the field. #BladderEpiCheck #Oncology

[NUCLEIX @NUCLEIX2]

Great discussions here at the Masterclass on Muscle-invasive bladder cancer, April 16 & 17 in Amsterdam, the Netherlands.
It was a pleasure to reconnect with Prof. Prof Param Mariappan during the congress. #innovation #oncology #BladderEpiCheck

[NUCLEIX @NUCLEIX2]

We're pleased to share that @EurUrolOncol recently published results showcasing the implications of implementing Bladder EpiCheck® in conjunction with white light cystoscopy for #NMIBC surveillance in high-grade recurrence. Learn more: https://t.co/uj2vpmKp3p

[NUCLEIX @NUCLEIX2]

Let's meet during the 10th BLADDR edition of the Mirrors of Medicine Global Forum in GU Oncology, taking place on December 3–4 in Lisbon, Portugal. Once again, the latest updates on Bladder EpiCheck®. Always a pleasure meeting @DrFelixGuerrero .
#Bladdr25 #Bladderepicheck

[NUCLEIX @NUCLEIX2]

We're committed to advancing early detection solutions that can transform outcomes for those at risk of #lungcancer, and this month, we join the global community in recognizing #LungCancerAwarenessMonth. We stand with @GO2forLungCancr! Learn more: https://t.co/yvholuiwx7

[NUCLEIX @NUCLEIX2]

Let's meet during the 3rd UROonco, June 19-21 in Seville. Once again, the latest updates on Bladder EpiCheck®. Always a pleasure meeting Dr @RobertoContieri and Dr @MATTIANICOLASA1
@Uroweb
#Oncology

[NUCLEIX @NUCLEIX2]

Let's meet during the 12th Scottish Bladder Cancer Symposium, May 29-30 in Edinburgh. Once again, the latest updates on Bladder EpiCheck®. Always a pleasure meeting Prof @ParamMariappan and Prof @UroDocAsh @MenariniDiagUK @NHS_Lothian

[NUCLEIX @NUCLEIX2]

#DidYouKnow bladder cancer is the 6th most common cancer in the US & the 5th most common cancer in Europe? At Nucleix, our non-invasive, urine-based test, Bladder EpiCheck® provides physicians & their patients with a simple, non-invasive urine test to detect disease recurrence.

[NUCLEIX @NUCLEIX2]

This week, we’re presenting an abstract showcasing the performance and clinical utility of Bladder EpiCheck® in #NMIBC monitoring at the @AmerUrological 2025 Annual Meeting. Learn more: https://t.co/AuWJGAXaxE #AUA25

[NUCLEIX @NUCLEIX2]

Let's meet during the MIBC Masterclass, Amsterdam, the Netherlands on April 10-11, 2025. As always, the latest updates on Bladder EpiCheck®; What else...

[NUCLEIX @NUCLEIX2]

In partnership with @NHS_Lothian, we presented data on the potential of Bladder EpiCheck® at #EAU25, showcasing the potential of the test to increase the detection of High-Grade recurrences in #NMIBC patients by 65%. https://t.co/Utpn3P8a65 @ParamMariappan #innovation

[NUCLEIX @NUCLEIX2]

Let's meet during the ESU-ESOU Masterclass on Non-muscle-invasive bladder cancer, which will take place on February 27 & 28, 2025 in Prague, Czech Republic. As always, the latest updates on Bladder EpiCheck®; What else...
#innovation #Oncology #bladdercancer

[NUCLEIX @NUCLEIX2]

Glad to be attending Bladder-CAT in Sitges, Spain, from February 21-22. Stay tuned for updates on Bladder EpiCheck®. What else...

[NUCLEIX @NUCLEIX2]

Next week, our CEO, Chris Hibberd, will be presenting at the @Piper_Sandler Healthcare Conference. Connect with us onsite for 1x1 meetings to learn more about our #liquidbiopsy tests that aim to detect #cancer earlier, when treatment can be most effective for patients.

[NUCLEIX @NUCLEIX2]

#DYK lung cancer is the leading cause of cancer deaths in the US, but less than 1 in 10 eligible individuals adhere to screening guidelines? Learn more this National Lung Cancer Screening Day about our work to detect cancer early in high-risk populations. https://t.co/3No6jpeViV

[NUCLEIX @NUCLEIX2]

Last month, our CSO, Mathias Ehrich, presented at @CHI_Healthtech’s Next Gen Dx Summit. Thank you to all who attended our session to learn more about our approach to detect cancer earlier when treatment can be most effective for patients.

[NUCLEIX @NUCLEIX2]

We've announced a commercial agreement w/ A. Menarini Diagnostics for the exclusive distribution of Bladder EpiCheck® in Europe. Learn more about our aim to accelerate the adoption of Bladder EpiCheck® to transform bladder cancer care. https://t.co/I8U8EYA9vk @ESP_Pathology

[NUCLEIX @NUCLEIX2]

This week, our CSO, Mathias Ehrich, will be presenting at the @CHI_Healthtech Next Gen Dx Summit. Learn more about his presentation on early cancer surveillance and how we are aiming to revolutionize cancer treatment with earlier disease detection here: https://t.co/4YbmT0BTkC

[NUCLEIX @NUCLEIX2]

Glad to be part of the ongoing second edition of the European onco-urological event, UROonco24! 🌟 Currently taking place in the historic city of Budapest, Hungary from 20-22 June 2024. Stay connected for the latest updates on Bladder EpiCheck®, What else......